Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates

While awaiting Phase III data on its partnered cancer vaccine Stimuvax, the Seattle biotech is advancing its own PI3 kinase inhibitor and follow-on vaccine projects.